All In Biotech

Drug Trial Radar · NCT04663347

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

543

Actual

Start

Nov 3, 2020

Primary completion

Sep 30, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Dec 11, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL). The aim of the first part of the trial is to identify the most appropriate dose of epcoritamab, and the aim of the second part of the trial is to assess the selected epcoritamab dose in a larger group of participants with B-NHL. All participants in this trial will receive either epcoritamab alone, or epcoritamab combined with another standard treatment regimen, with a total of 10 different treatment arms being studied. Trial details include: * The treatment duration for each participant depends upon which arm of treatment they are assigned to. * The visit frequency for each participant depends upon which arm of treatment they are assigned to, but will be weekly to start for all participants, then will decrease to either: every 2 weeks, or every 3 weeks, or every 4 weeks, or every 8 weeks. * All participants will receive active drug; no one will be given placebo. Participants who receive treatment with epcoritamab will have it injected right under the skin. Participants will receive a different regimen of epcoritamab depending upon which arm of treatment they are assigned. Participants who receive standard treatments will have intravenous (IV) infusions and/or oral administration of those treatments. Participants will receive a different standard treatment regimen depending upon which arm of treatment they are assigned.

Conditions

  • Diffuse Large B-Cell Lymphoma
  • Follicular Lymphoma

Interventions

  • rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisoneDrug

    6 cycles (21-day cycles)

  • rituximab and lenalidomideDrug

    rituximab 6 cycles and lenalidomide 12 cycles (28-day cycles)

  • rituximab and bendamustineDrug

    6 cycles (28-day cycles)

  • rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatinDrug

    3 cycles (21-day cycles)

  • gemcitabine and oxaliplatinDrug

    4 cycles (28-day cycles)

  • EpcoritamabBiological

    Every week in cycle 1-4, every 3 weeks in cycle 5 and 6, followed by every 4 weeks in cycle 7 for a total of 1 year.

  • rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisoneDrug

    6 cycles (21-day cycles)

  • LenalidomideDrug

    12 cycles (28-day cycles)

  • rituximab, ifosfamide, carboplatin, and etoposide phosphateDrug

    3 cycles (21-day cycles)

  • EpcoritamabBiological

    Every week in cycle 1-3, every 2 weeks in cycle 4-9, followed by every 4 weeks for a total of 2 years.

  • EpcoritamabBiological

    Every week in cycle 1 and 2, followed by every 4 weeks for a total of 2 years.

  • EpcoritamabBiological

    Every week in cycle 1 and then every 8 weeks for a total of 2 years.

  • EpcoritamabBiological

    Every week in cycles 1 and 2, then every 3 weeks in cycles 3 to 6 and then every 4 weeks for cycles 7 and 8.

  • EpcoritamabBiological

    Every week in cycle 1-3 and then every 4 weeks for a total of 2 years.

  • EpcoritamabBiological

    Every week in cycle 1-4, every 2 weeks in cycle 5-9 followed by every 4 weeks until ASCT or disease progression.

  • EpcoritamabBiological

    Eligible participants will receive subcutaneous (SC) epcoritamab in 28-day cycles. Fixed-treatment epcoritamab will be administered following a 2-Set Up Dosing regimen in Cycle 1. There will be 2 cohorts, 2a and 2b with different dosing schedules. Cohort 2a will be dosed weekly (QW) in Cycles 1-3, once every 2 weeks (Q2W) in Cycles 4-9, and once every 4 weeks (Q4W) in Cycle 10 and beyond for up to 2 years. In cohort 2b, an alternate dosing schedule for epcoritamab will be explored: epcoritamab administered QW for Cycles 1-2 only, then Q4W in Cycle 3 and beyond for up to 2 years.

  • Rituximab and LenalidomideDrug

    Rituximab 375 milligrams per meter squared (mg/m\^2) will be administered intravenously QW in Cycle 1 and Q4W in Cycles 2-5. Lenalidomide 20 mg will be administered orally daily for 21 days for 12 cycles.

  • EpcoritamabBiological

    Cycle 1-3 every week, every other week Cycle 4-9 and then Q4W until progression or unacceptable toxicity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With Dose limiting Toxicities (DLTs)Time frame: During the first cycle (Cycle length= 28 days) in each cohort
  2. Part 1 and Part 2 (Arms 1-5, 7 and 10): Number of Participants With Adverse Events (AEs)Time frame: From first dose of drug until either 60 days after last dose, date participant withdraws consent, date participant starts a new systemic anticancer therapy, or date participant dies, whichever occurs first (up to approximately 3 years)
  3. Part 2 (Except Arm 7): Overall Response Rate (ORR)Time frame: Up to 3 years

Locations

57 sites in 13 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • University of California San Francisco

    San Francisco, California

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan Comprehensive Cancer Center Michigan Medicine

    Ann Arbor, Michigan

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Mount Sinai

    New York, New York

  • Memorial Sloan Kettering CC

    New York, New York

  • Levine Cancer Center

    Charlotte, North Carolina

  • Southwestern Medical Center

    Dallas, Texas

  • Austin Health

    Heidelberg, Australia

  • Linear Clinical Research Limited

    Nedlands, Australia

  • AZ Sint-Jan

    Bruges, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • CHU UCL Namur Site Godinne

    Yvoir, Belgium

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia

  • Fakultni nemocnice Ostrava

    Ostrava - Poruba, Czechia

  • Fakultni nemocnice v Motole

    Prague, Czechia

  • Vseobecna Fakultni Nemocnice

    Prague, Czechia

  • Århus Hospital

    Aarhus, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Odense University Hospital

    Odense, Denmark

  • Vejle Sygehus

    Vejle, Denmark

  • Kuopio University Hospital

    Kuopio, Finland

  • HUS Cancer Center

    Lahti, Finland

  • Hopital Claude Huriez - CHRU Lille

    Lille, France

  • Hôpital de la Timone

    Marseille, France

  • Hôpital Saint-Louis

    Paris, France

  • Centre Hospitalier Lyon Sud

    Pierre-Bénite, France

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)

    Bergamo, Italy

  • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS

    Bologna, Italy

  • Fondazione del Piemonte per l Oncologia Istituto di Candiolo IRCCS

    Candiolo, Italy

  • IRCCS Istituto Scientifico Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST

    Meldola, Italy

  • Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico

    Milan, Italy

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia

    Reggio Emilia, Italy

  • Amsterdam UMC, Locatie VUMC

    Amsterdam, Netherlands

  • Universitair Medisch Centrum Groningen (UMCG)

    Groningen, Netherlands

  • Leids Universitair Medisch Centrum

    Leiden, Netherlands

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.